Trials / Terminated
TerminatedNCT01424033
A Clinical Trial for CTD-ILD Treatment
Clinical Trial of Oral Medication for CTD-ILD Treatment
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- University of Michigan · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
Detailed description
The investigators will assess tolerability and safety at scheduled intervals via standard of care physical exam findings, monitoring complete blood count, serum chemistry, and pulmonary function tests, along with patient reports of medication intolerance and change in symptoms of dyspnea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N-Acetylcysteine | 600mg by mouth, three times daily for 12 months |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-02-01
- First posted
- 2011-08-26
- Last updated
- 2017-04-06
- Results posted
- 2016-02-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01424033. Inclusion in this directory is not an endorsement.